摘要
目的:探讨依达拉奉治疗急性脑梗塞的疗效,降低并发症的发生率。方法:抽取我院2009年1月至2011年1月收治的60例急性脑梗塞患者,随机分为两组。对照组30例,行常规内科治疗。实验组30例,在常规内科治疗的基础上加用依达拉奉静脉滴注。术后随访1-3个月,治疗后疗效对比评估采用中国卒中量表(CSS)和日常生活能力(ADL)两项进行评定,并对疗效结果进行统计。结果:两组患者相比,治疗前两项评分差异均无统计学意义(P>0.05),治疗后实验组CSS和ADL评分均优于对照组,差异有统计学意义(P<0.05)。实验组术后显效22例,有效6例,无效2例,总有效率(包括显效和有效)为92.8%优于对照组,差异有统计学意义(P<0.05)。结论:早期应用依达拉奉对急性脑梗塞患者疗效显著,有利于提高其日常生活能力,是一种安全有效的药物,值得在临床上推广使用。
Objective: To explore edaravone in treatment of acute cerebral infarction.Method: We randomly selected 60 patients with acute cerebral infarction,They were randomly divided into two groups.The control group received routine medical treatment,the experimental group received intravenous infusion of edaravone.Follow-up for 1 to 3 months and then used Chinese Stroke Scale(CSS) and activities of daily living(ADL) to evaluate the effect and statistics of its clinical efficacy and quality of life.Result: Experimental group having an effect in 22 cases,effective 6 cases,is not valid in 2 cases,total efficiency(including having an effect and valid) is 92.8%,higher than the control group(P 0.05).Conclusion: Early therapeutic effect of edaravone on acute cerebral infarction patients is significant,safe and effective,It can enhance their daily life and improve the quality of life.
出处
《河北医学》
CAS
2012年第3期338-340,共3页
Hebei Medicine
关键词
脑梗死
依达拉奉
急性
Cerebral infarction
Edaravone
Acute